Adial Pharmaceuticals, Inc. Form DEFR14A: Revised definitive proxy materials
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2025-06-27: Form DEFR14A; Description PROXY STATEMENT; Document ea0243378-04.htm.
- 2021-08-27: Form DEFR14A; Description DEFINITIVE REVISED PROXY STATEMENT; Document ea146534-defr14a_adialpharma.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2025-06-27 | DEFR14A | PROXY STATEMENT | ea0243378-04.htm | |
| 2021-08-27 | DEFR14A | DEFINITIVE REVISED PROXY STATEMENT | ea146534-defr14a_adialpharma.htm |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |